Press Release – New York, NY – September 29, 2025 – Sichenzia Ross Ference Carmel LLP announced that it has represented Lexaria Bioscience Corp. (Nasdaq: LEXX) (NASDAQ: LEXXW), a global innovator in drug delivery platforms, in its recently closed $4 million registered direct offering and concurrent private placement of warrants.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The SRFC team was led by partners Gregory Sichenzia and Avital Perlman and included associates Christian Lichtenberger and Benasz Hansotia.
